Veenat 400mg Tablet

Blood cancer (Chronic myeloid leukaemia)
Gastrointestinal stromal tumour
Treatment of Cancer

Veenat 400mg Tablet may cause some serious and unwanted side effects. It requires immediate medical attention; otherwise, it can also lead to a higher risk. Discuss the risks and benefits of Veenat 400mg with a medical advisor before starting the treatment. 
Vomiting 
Diarrhea 
Rash 
Abdominal pain 
Loss of appetite
Indigestion Irregular heartbeat
Shortness of breath
Fatigue
Muscle cramp
Joint pain
Nausea
Headache
Blurred vision
Sore throat

Take Veenat 400mg Tablet as prescribed by your doctor. Do not crush or chew. Do not take this medicine on an empty stomach.  
In case of an overdose, the doctor will provide emergency medical treatment. 

Veenat 400mg Tablet is a protein tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the consecutive abnormal tyrosine inhibitor created by the Philadelphia chromosome abnormality in CML. After the oral administration, the effect of this medicine can be observed in 2-4 hours. 

In case of an overdose of  Veenat 400mg Tablet, the doctor will provide emergency medical treatment. 

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

Arora, R., Sharma, M., Monif, T., & Iyer, S. (2024). A multi‑centric bioequivalence trial in Ph+ chronic myeloid leukemia patients to assess bioequivalence and safety evaluation of generic imatinib mesylate 400 mg tablets. Cancer Research and Treatment, 48(3), 1120–1129.

Generic Imatinib–Free Trial‑in‑CML–Chronic Phase Study. (2023). Indian Journal of Medical Research. Feasibility of treatment‑free remission with generic imatinib in chronic‑phase CML.

Ghadyalpatil, N., Banawali, S., Kurkure, P., Arora, B., Bansal, S., Amare, P., Choughule, A., Soy, L., & Singh, R. (2023). Efficacy and tolerability of imatinib mesylate in pediatric chronic myeloid leukemia in a large cohort: Results from a tertiary care referral center in India. Journal of Clinical Oncology, 27(15-100), 10047.

Monitoring of response to therapy with imatinib mesylate in chronic myeloid leukemia in chronic phase (CML‑CP). (2024). Retrospective analysis showing comparable clinical and molecular outcomes with Veenat vs. Gleevec®.

Srivastava, S., & Dutt, S. (2023). Imatinib mesylate resistance and mutations: An Indian experience. Indian Journal of Medical and Paediatric Oncology, 34(3), 213–220.

The cancer (2025). Monitoring of disease activity in CML‑CP patients treated with Indian generic Veenat (Natco) imatinib mesylate: A tertiary care experience. Cancer Translational Medicine, 1(2).